{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:42:26Z","timestamp":1784432546767,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","award":["\u00daNKP-21-4"],"award-info":[{"award-number":["\u00daNKP-21-4"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","award":["\u00daNKP-21-4"],"award-info":[{"award-number":["\u00daNKP-21-4"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Until recently, little was known about the susceptibility pattern of <jats:italic>Cyberlindnera fabianii<\/jats:italic> (<jats:italic>Cy. fabianii<\/jats:italic>) planktonic cells and biofilms regarding the most frequently administered systemic antifungals, despite the high mortality rate and its potential role in catheter-related infections. In the current study, the activity of fluconazole, amphotericin B and echinocandins (anidulafungin, caspofungin and micafungin) was determined against planktonic and sessile cells of <jats:italic>Cy. fabianii<\/jats:italic> clinical isolates (<jats:italic>n<\/jats:italic>\u2009=\u20098). Planktonic minimum inhibitory concentrations (MICs) ranged from 1 to 2, from 0.25 to 1, from 0.015 to 0.06, from 0.03 to 0.12 and from 0.25 to 0.5\u00a0mg\/l for fluconazole, amphotericin B, anidulafungin, caspofungin and micafungin, respectively. One-day-old biofilms were highly resistant to fluconazole (MIC ranged from 512 to\u2009&gt;\u2009512) compared to planktonic counterparts, but not to amphotericin B (MIC ranged from 0.25 to 2\u00a0mg\/l) and echinocandins (MIC ranged from 0.06 to 2\u00a0mg\/l). Based on the calculated planktonic killing rates, the highest activity was observed in the case of anidulafungin (<jats:italic>k<\/jats:italic> values ranged from 0.37 to 2.09), while micafungin, caspofungin, amphotericin B and fluconazole exerted 0.46\u20131.47, 0.14\u20130.86, \u22120.03 to 2.08 and \u22120.15 to 0.09 killing rate value ranges, respectively. The obtained in vitro planktonic and sessile susceptibility patterns suggest that echinocandins and amphotericin B may be the most reliable treatment option for the treatment of <jats:italic>Cy. fabianii<\/jats:italic> infections.<\/jats:p>","DOI":"10.1007\/s11046-022-00688-9","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T15:04:34Z","timestamp":1668783874000},"page":"111-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms"],"prefix":"10.1007","volume":"188","author":[{"given":"Zolt\u00e1n","family":"T\u00f3th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliz","family":"Boz\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1t\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Forg\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barna","family":"Kelentey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Majoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"4","key":"688_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/12298093.2019.1651592","volume":"47","author":"JH Park","year":"2019","unstructured":"Park JH, Oh J, Sang H, Shrestha B, Lee H, Koo J, Cho SI, Choi JS, Lee MH, Kim J, Sung GH. Identification and Antifungal Susceptibility Profiles of Cyberlindnera fabianii in Korea. Mycobiology. 2019;47(4):449\u201356. https:\/\/doi.org\/10.1080\/12298093.2019.1651592.","journal-title":"Mycobiology"},{"issue":"4","key":"688_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/myc.12454","volume":"59","author":"L Svobodova","year":"2016","unstructured":"Svobodova L, Bednarova D, Ruzicka F, Chrenkova V, Dobias R, Mallatova N, Buchta V, Kocmanova I, Olisarova P, Stromerova N, Thongsri Y, Hamal P. High frequency of Candida fabianii among clinical isolates biochemically identified as Candida pelliculosa and Candida utilis. Mycoses. 2016;59(4):241\u20136. https:\/\/doi.org\/10.1111\/myc.12454.","journal-title":"Mycoses"},{"issue":"7","key":"688_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/mmy\/myy148","volume":"57","author":"A Arastehfar","year":"2019","unstructured":"Arastehfar A, Fang W, Al-Hatmi AMS, Afsarian MH, Daneshnia F, Bakhtiari M, Sadati SK, Badali H, Khodavaisy S, Hagen F, Liao W, Pan W, Zomorodian K, Boekhout T. Unequivocal identification of an underestimated opportunistic yeast species, Cyberlindnera fabianii, and its close relatives using a dual-function PCR and literature review of published cases. Med Mycol. 2019;57(7):833\u201340. https:\/\/doi.org\/10.1093\/mmy\/myy148.","journal-title":"Med Mycol"},{"issue":"6","key":"688_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/13693780802078180","volume":"46","author":"P Hamal","year":"2008","unstructured":"Hamal P, Ostransky J, Dendis M, Horv\u00e1th R, Ruzicka F, Buchta V, Vejsova M, Sauer P, Hejnar P, Raclavsky V. A case of endocarditis caused by the yeast Pichia fabianii with biofilm production and developed in vitro resistance to azoles in the course of antifungal treatment. Med Mycol. 2008;46(6):601\u20135. https:\/\/doi.org\/10.1080\/13693780802078180.","journal-title":"Med Mycol"},{"key":"688_CR5","doi-asserted-by":"publisher","unstructured":"Jindal N, Arora S, Dhuria N, Arora D. Cyberlindnera (Pichia) fabianii infection in a neutropenic child: importance of molecular identification. JMM Case Reports. 2015;2(4) https:\/\/doi.org\/10.1099\/jmmcr.0.000033","DOI":"10.1099\/jmmcr.0.000033"},{"issue":"1","key":"688_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/myc.12846","volume":"62","author":"N Al-Sweih","year":"2019","unstructured":"Al-Sweih N, Ahmad S, Khan S, Joseph L, Asadzadeh M, Khan Z. Cyberlindnera fabianii fungaemia outbreak in preterm neonates in Kuwait and literature review. Mycoses. 2019;62(1):51\u201361. https:\/\/doi.org\/10.1111\/myc.12846.","journal-title":"Mycoses"},{"key":"688_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mmcr.2019.07.004","volume":"26","author":"M Desai","year":"2019","unstructured":"Desai M, Nitta B, Dhanani H, Djurkovic S, Katugaha S. Multiple organ dysfunction syndrome and death secondary to Cyberlindnera fabianii. Med Mycol Case Rep. 2019;26:1\u20134. https:\/\/doi.org\/10.1016\/j.mmcr.2019.07.004.","journal-title":"Med Mycol Case Rep"},{"issue":"3","key":"688_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/13693786.2011.587455","volume":"50","author":"F Gabriel","year":"2012","unstructured":"Gabriel F, Noel T, Accoceberry I. Lindnera (Pichia) fabianii blood infection after mesenteric ischemia. Med Mycol. 2012;50(3):310\u20134. https:\/\/doi.org\/10.3109\/13693786.2011.587455.","journal-title":"Med Mycol"},{"key":"688_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1756-0500-6-77","volume":"6","author":"Y Wu","year":"2013","unstructured":"Wu Y, Wang J, Li W, Jia H, Che J, Lu J, Liu L, Cheng Y. Pichia fabianii blood infection in a premature infant in China: case report. BMC Res Notes. 2013;6:77. https:\/\/doi.org\/10.1186\/1756-0500-6-77.","journal-title":"BMC Res Notes"},{"issue":"6","key":"688_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s15010-017-1062-8","volume":"45","author":"H Hof","year":"2017","unstructured":"Hof H, Amann V, Tauber C, Paulun A. Peritonitis in a neonate due to Cyberlindnera fabianii, an ascomycetic yeast. Infection. 2017;45(6):921\u20134. https:\/\/doi.org\/10.1007\/s15010-017-1062-8.","journal-title":"Infection"},{"key":"688_CR11","unstructured":"Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts \u2013 4th Edition. M27 Ed4. CLSI, Wayne, PA, USA, 2017."},{"issue":"3\u20134","key":"688_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11046-014-9799-4","volume":"178","author":"R Kov\u00e1cs","year":"2014","unstructured":"Kov\u00e1cs R, Gesztelyi R, Perlin DS, Kardos G, Dom\u00e1n M, Ber\u00e9nyi R, Majoros L. Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum. Mycopathologia. 2014;178(3\u20134):197\u2013206. https:\/\/doi.org\/10.1007\/s11046-014-9799-4.","journal-title":"Mycopathologia"},{"issue":"6","key":"688_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737\u201379. https:\/\/doi.org\/10.1007\/s15010-017-1042-z.","journal-title":"Infection"},{"issue":"3","key":"688_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","volume":"57","author":"RE Wasmann","year":"2018","unstructured":"Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Br\u00fcggemann RJ. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clin Pharmacokinet. 2018;57(3):267\u201386. https:\/\/doi.org\/10.1007\/s40262-017-0578-5.","journal-title":"Clin Pharmacokinet"},{"key":"688_CR15","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.3791\/2437","volume":"47","author":"GA O'Toole","year":"2011","unstructured":"O\u2019Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;47:2437. https:\/\/doi.org\/10.3791\/2437.","journal-title":"J Vis Exp"},{"issue":"4","key":"688_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/mmy\/myx062","volume":"56","author":"F Nagy","year":"2018","unstructured":"Nagy F, Boz\u00f3 A, T\u00f3th Z, Dar\u00f3czi L, Majoros L, Kov\u00e1cs R. In vitro antifungal susceptibility patterns of planktonic and sessile Candida kefyr clinical isolates. Med Mycol. 2018;56(4):493\u2013500. https:\/\/doi.org\/10.1093\/mmy\/myx062.","journal-title":"Med Mycol"},{"key":"688_CR17","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts \u2013 2nd Edition M60 Ed2 CLSI, Wayne, PA, USA, 2017."},{"issue":"2","key":"688_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01253-21","volume":"10","author":"H Lee","year":"2022","unstructured":"Lee H, Choi SH, Oh J, Koo J, Lee HJ, Cho SI, Shin JH, Lee HK, Kim SY, Lee CH, Kim YR, Sohn YH, Kim WJ, Ryu SW, Sung GH, Kim J. Comparison of Six Antifungal Susceptibilities of 11 Candida Species Using the VITEK2 AST-YS08 Card and Broth Microdilution Method. Microbiol Spectr. 2022;10(2): e0125321. https:\/\/doi.org\/10.1128\/spectrum.01253-21.","journal-title":"Microbiol Spectr"},{"key":"688_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3389\/fmicb.2020.01401","volume":"11","author":"Y Song","year":"2020","unstructured":"Song Y, Chen X, Yan Y, Wan Z, Liu W, Li R. Prevalence and Antifungal Susceptibility of Pathogenic Yeasts in China: A 10-Year Retrospective Study in a Teaching Hospital. Front Microbiol. 2020;11:1401. https:\/\/doi.org\/10.3389\/fmicb.2020.01401.","journal-title":"Front Microbiol"},{"key":"688_CR20","doi-asserted-by":"publisher","unstructured":"Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):i4-i13. doi: https:\/\/doi.org\/10.1093\/jac\/dkx444.","DOI":"10.1093\/jac\/dkx444"},{"issue":"1","key":"688_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","volume":"3","author":"G Eschenauer","year":"2007","unstructured":"Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3(1):71\u201397. https:\/\/doi.org\/10.2147\/tcrm.2007.3.1.71.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"688_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019653","volume":"5","author":"AJ Lepak","year":"2014","unstructured":"Lepak AJ, Andes DR. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med. 2014;5(5): a019653. https:\/\/doi.org\/10.1101\/cshperspect.a019653.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"688_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/myc.13049","volume":"63","author":"E Vit\u00e1lis","year":"2020","unstructured":"Vit\u00e1lis E, Nagy F, T\u00f3th Z, Forg\u00e1cs L, Boz\u00f3 A, Kardos G, Majoros L, Kov\u00e1cs R. Candida biofilm production is associated with higher mortality in patients with candidaemia. Mycoses. 2020;63(4):352\u201360. https:\/\/doi.org\/10.1111\/myc.13049.","journal-title":"Mycoses"},{"issue":"1","key":"688_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmi.2015.09.018","volume":"22","author":"R Rajendran","year":"2016","unstructured":"Rajendran R, Sherry L, Nile CJ, Sherriff A, Johnson EM, Hanson MF, Williams C, Munro CA, Jones BJ, Ramage G. Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012\u20132013. Clin Microbiol Infect. 2016;22(1):87\u201393. https:\/\/doi.org\/10.1016\/j.cmi.2015.09.018.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"688_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.coph.2013.08.008","volume":"13","author":"CG Pierce","year":"2013","unstructured":"Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, L\u00f3pez-Ribot JL. Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013;13(5):726\u201330. https:\/\/doi.org\/10.1016\/j.coph.2013.08.008.","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"688_CR26","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1086\/587101","volume":"46","author":"M Nucci","year":"2008","unstructured":"Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis. 2008;46(9):1426\u201333. https:\/\/doi.org\/10.1086\/587101.","journal-title":"Clin Infect Dis"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-022-00688-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-022-00688-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-022-00688-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:05:37Z","timestamp":1683756337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-022-00688-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":26,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s11046-022-00688-9","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L. Majoros has received conference travel grants from MSD, Cidara, Astellas, and Pfizer. Others: None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional ethics committee (University of Debrecen, Regional and Institutional Research Ethics Committee [DE RKEB\/IKEB], permission number (5775-2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}